Being selected for an oral presentation at a prestigious conference like AAIC not only validates the potential of Longeveron's Lomecel-B in treating Alzheimer's but also puts the company in a favorable position to attract further investment and partnerships. This visibility could lead to a positive short-term impact on LGVN's stock price as it highlights the company's progress and potential in a high-impact area of medical research.